Eden Ben, CEO of Amorphical, and Dr Yigal Blum, CTO of Amorphical, argue that targeting the hostile tumour microenvironment is the key to effectively treating this aggressive cancer.  For years, the conversation around pancreatic cancer has focused on the tumour itself, the "broken" cells that won't stop growing. In 2026, our toolbox for attacking those […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!